Found 162 articles for: "infliximab"
RESIDENT ROUNDS: PART III
March 2019 | Volume 18 | Issue 3 | Original Article | 307 | Copyright © March 2019
Case Report: Triple Combination Therapy for Recalcitrant Perineal Pyoderma Gangrenosum...
Read MoreOnset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update
March 2019 | Volume 18 | Issue 3 | Original Article | 229 | Copyright © March 2019
Objectives: The time that drugs for moderate-to-severe psoriasis take to see a clinically meaningful improvement (TOA) is one of the most important attributes of treatment success. This study synth...
Read MoreNavigating Targeted Therapeutics in Dermatology: Biologics and Small Molecules
December 2018 | Volume 17 | Issue 12 | Features | 1330 | Copyright © December 2018
Dermatology is entering an exciting era with new, targeted immune-modulating medications for treating a variety of dermatologic conditions including psoriasis, atopic dermatitis (AD), and hidradenitis...
Read MoreAdverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis
November 2018 | Volume 17 | Issue 11 | Original Article | 1211 | Copyright © November 2018
OBJECTIVE: To assess the real-world risk of developing adverse medical conditions (AMCs) among patients with psoriasis treated with biologic therapies or conventional systemic/topical therapies (CST/t...
Read MoreOpen-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
October 2018 | Volume 17 | Issue 10 | Original Article | 1078 | Copyright © October 2018
INTRODUCTION: Response to etanercept therapy in patients who have failed apremilast therapy has not been well characterized. METHODS: In this multicenter, open-label, single-arm, phase 4, estimatio...
Read MoreEfficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial
August 2018 | Volume 17 | Issue 8 | Original Article | 873 | Copyright © August 2018
Background: Toreforant is a selective histamine H4 receptor antagonist. H4 receptor activation may play a role in immune-mediated inflammation in psoriasis. Objective: To evaluate Toreforant effica...
Read MoreLong-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
August 2018 | Volume 17 | Issue 8 | Original Article | 826 | Copyright © August 2018
Background: Due to the chronic nature of psoriasis, it is important to assess the sustained response of treatments over time. Objective: To assess the efficacy of continuous treatment with guselkumab...
Read MoreSuccessful Therapy of Severe Oro-Labial Herpes Simplex With Muco-Adhesive Acyclovir
April 2018 | Volume 17 | Issue 4 | Case Reports | 479 | Copyright © April 2018
Although muco-adhesive acyclovir 50mg tablets are only approved for the management of recurrent oro-labial HSV-1 infections, their ability to achieve extremely high concentrations in saliva and oral t...
Read MoreOnset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis
March 2018 | Volume 17 | Issue 3 | Original Article | 247 | Copyright © March 2018
BACKGROUND: The advent of biologics has improved patient outcomes in the treatment of moderate-to-severe psoriasis. The time it takes for patients to see clinically meaningful improvement is an import...
Read MorePrevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis
February 2018 | Volume 17 | Issue 2 | Original Article | 187 | Copyright © February 2018
IMPORTANCE: While psoriasis (Ps) is mainly characterized as an adult disease, it can also ...
Read MoreRecalcitrant Diffuse Cutaneous Sarcoidosis With Perianal Involvement Responding to Adalimumab
December 2017 | Volume 16 | Issue 12 | Editorials | 1305 | Copyright © December 2017
Recalcitrant cutaneous sarcoidosis with perianal involvement is rare. To our knowledge we present the first documented case of cutaneous sarcoidosis with perianal involvement successfully treated w...
Read MoreCost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis
December 2017 | Volume 16 | Issue 12 | Original Article | 1246 | Copyright © December 2017
BACKGROUND: Newer psoriasis treatments can achieve greater levels of effcacy than older systemic therapies; however, current pso-riasis costs are substantial. We sought to estimate costs per additi...
Read MoreThe Latest Drugs and Small Molecule Inhibitors for Skin and Hair
December 2017 | Volume 16 | Issue 12 | Original Article | 1224 | Copyright © December 2017
Biologic drugs, a novel class of agents engineered to target specifc mediators of infammation, and small-molecule inhibitors that pen-etrate the cell membrane to interact with targets inside a cell...
Read MoreGranuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma
October 2017 | Volume 16 | Issue 10 | Case Reports | 1050 | Copyright © October 2017
Numerous cutaneous manifestations have been associated with use of BRAF inhibitors, including two previously reported cases of granuloma annulare (GA) eruptions associated with vemurafenib therapy. Bo...
Read MoreEvaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis
October 2017 | Volume 16 | Issue 10 | Original Article | 1002 | Copyright © October 2017
BACKGROUND: Psoriasis is associated with increased risk of major adverse cardiovascular events (MACE). OBJECTIVES: Compare MACE risk with biologics vs topical/phototherapy use. METHODS: Psoriasis Lo...
Read MoreUnderstanding State Regulation of Biosimilars and Effect on Prescribers
October 2017 | Volume 16 | Issue 10 | Original Article | 995 | Copyright © October 2017
Biologics are a mainstay of treatment for many dermatologic conditions, however the high costs can be prohibitive for many patients. A growing market of biosimilar drugs is emerging with the hope of p...
Read MoreAdalimumab in Chronic Plaque Psoriasis: A Clinical Guide
August 2017 | Volume 16 | Issue 8 | Original Article | 779 | Copyright © August 2017
Psoriasis is a common, inflammatory disease that manifests itself as lesions on the skin, which greatly impacts the physical and psychological wellbeing of those affected. The current goal of treat...
Read MorePostoperative Pyoderma Gangrenosum Following Video-Assisted Thoracic Surgery
July 2017 | Volume 16 | Issue 7 | Case Reports | 711 | Copyright © July 2017
Pyoderma gangrenosum (PG) is a neutrophilic, ulcerative dermatosis that can develop at sites of cutaneous trauma, including surgical incisions, a phenomenon known as pathergy. The characteristic le...
Read MoreInjection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis
July 2017 | Volume 16 | Issue 7 | Case Reports | 695 | Copyright © July 2017
Psoriasis is a chronic inflammatory cutaneous disease that affects 2-3% of the general population. Up to 30% of patients with psoriasis also develop psoriatic arthritis, a chronic inflammatory and ...
Read MoreDrivers of Healthcare Costs Among the Costliest Patients With Psoriasis Over Three Years in a United States Health Plan
July 2017 | Volume 16 | Issue 7 | Original Article | 651 | Copyright © July 2017
OBJECTIVE: To compare patients with psoriasis by cost level over 3 years.
METHODS: Psoriasis patients in a large US health plan in 2011-2013 were identified. Four groups were created by h...
Read More